Lunit to Advance Singapore’s Healthcare Landscape with AI-powered Chest Screening Solution Integrated into National AI Platform

Lunit INSIGHT CXR is now integrated into Singapore General Hospital and Changi General Hospital through AimSG, Singapore’s public healthcare platform for AI-powered medical imaging

SEOUL, South Korea, December 1, 2023 -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has joined forces with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore’s public healthcare system.

▲ Lunit's AI-powered chest X-ray analysis solution, 'Lunit INSIGHT CXR' (image: Lunit)

Following the agreement, Lunit successfully delivered Lunit INSIGHT CXR to NTT DATA, which, in turn, facilitated the delivery to Synapxe, Singapore’s national health-tech agency. Utilizing AimSG, Singapore’s national AI platform for medical imaging, Synapxe integrated Lunit INSIGHT CXR into the clinical radiology workflow of two leading public hospitals: Singapore General Hospital (SGH) and Changi General Hospital (CGH). Both are award-winning public hospitals, each with over 1,000 beds, and are members of SingHealth, Singapore’s largest group of public healthcare institutions.

With the integration of Lunit INSIGHT CXR, both hospitals aim to enhance the efficiency of chest screening, offering innovative medical services with heightened accuracy for patients across the country.

AimSG Pilot Project: A Collaborative Leap Towards AI-driven Healthcare Transformation

The AimSG platform is a collaboration amongst Synapxe, SingHealth, Lunit, NTT DATA, and its partners (DeepTek and CARPL), with support from Singapore’s Ministry of Health (MoH) and Smart Nation Singapore. AimSG facilitates seamless integration of AI imaging solutions, like Lunit INSIGHT CXR, into existing clinical radiology workflows. This collaboration enhances medical professionals’ diagnostic capabilities and efficiency, furthering the mission of preventive, predictive, and personalized medicine.

“The AimSG platform is an enabler that aims to accelerate Singapore public healthcare institutions to validate and deploy credible AI imaging models in a complex healthcare technology landscape,” said Glenn Neo, Head of Innovation Capabilities Enablement, Synapxe. “AimSG is an open and vendor-neutral platform that will serve multiple use cases that apply AI to clinical images, such as chest X-ray, mammogram, cardiac CT, and more.”

Healthcare institutions that have adopted Lunit’s AI solution through AimSG have had a positive response and are looking forward to improving the medical imaging workflow.

“The AimSG platform enables clinicians from public healthcare institutions to deploy AI algorithms to help them deliver better healthcare to the population, ultimately enhance our efforts to enable preventive, predictive, and personalized medicine,” said Dr. Charlene Liew, Director of Innovation, SingHealth Duke-NUS Radiological Sciences Academic Clinical Programme and Deputy Chief Medical Informatics Officer, Changi General Hospital.

“Harnessing Lunit’s AI solutions through AimSG and integrating the AI directly into our clinical workflow can potentially advance our ability to enhance the interpretation and diagnosis of chest diseases for patients. This holds the potential to facilitate and expedite patient care while minimizing the strain on the healthcare workforce,” said Dr Chan Lai Peng, Academic Vice-chair of Clinical Service Operations, SingHealth Duke-NUS Radiological Sciences Academic Clinical Programme and Head of Diagnostic Radiology, Singapore General Hospital.

“Taking part in the AimSG project and collaborating with our partners to bring Lunit INSIGHT CXR to Singapore’s public healthcare system is a significant step in our mission to advance the cancer care landscape worldwide,” said Brandon Suh, CEO of Lunit. “Considering Singapore’s position as the primary destination for medical AI companies in Southeast Asia and the largest contributor to the market in the region, this collaboration holds immense potential. It will not only bring significant benefits to Singapore but also pave the way for us to tap into the broader Southeast Asian market.”

If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.